
Heron Therapeutics (HRTX) Stock Forecast & Price Target
Heron Therapeutics (HRTX) Analyst Ratings
Bulls say
Heron Therapeutics is supported by strong clinical results from Exparel, which further entrench the product as an effective post-operative pain treatment in hospitals and outpatient clinics, reinforcing demand in a large and clinically relevant market. Despite the CINVANTI patent setback creating a meaningful overhang on the cash-flow story, the company still has multiple commercial assets that can support revenue resilience and help offset near-term legal uncertainty. The key fundamental driver is ZYNRELEF execution in 2026, since successful commercialization there could meaningfully improve sentiment and underpin a recovery from depressed levels.
Bears say
Heron Therapeutics is facing a deteriorating fundamental profile because the adverse CINVANTI patent ruling has undermined the company’s largest revenue and cash-flow anchor, with management withdrawing 2026 revenue and Adjusted EBITDA guidance and pausing planned sales-force expansion. ZYNRELEF and APONVIE are growing, but 2Q26 revenue of $37.7M and Adjusted EBITDA of $3.2M still leave the company too dependent on CINVANTI, while ZYNRELEF’s sequential ramp to $11.1M remains too slow to offset potential erosion. With only $42.7M of cash and cash equivalents against about $142.7M of debt at June 30, the balance sheet and uncertain runway create meaningful liquidity and financing risk.
This aggregate rating is based on analysts' research of Heron Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Heron Therapeutics (HRTX) Analyst Forecast & Price Prediction
Start investing in Heron Therapeutics (HRTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Heron Therapeutics (HRTX) Forecast
Heron Therapeutics (HRTX) Analyst Forecast & Price Prediction
Start investing in Heron Therapeutics (HRTX)
Order type
Buy in
Order amount
Est. shares
0 shares